News

BioVersys tops up capital by 24.2 million Swiss francs

BioVersys has raised 24.2 million Swiss francs in a series C funding round. The Basel-based pharmaceutical company plans to use this to develop a clinical pipeline of innovative therapies to combat antibiotic resistance and for targeted microbiome modulation.

BioVersys plans to develop a clinical pipeline of innovative therapies to combat antibiotic resistance. Generic image: Darko Stojanovic/Pixabay
BioVersys plans to develop a clinical pipeline of innovative therapies to combat antibiotic resistance. Generic image: Darko Stojanovic/Pixabay

BioVersys has received 24.2 million Swiss francs from investors in a series C funding round. According to an announcement from the pharmaceutical company, it will use the funds to start the first phase II clinical trials for two drug candidates as well as preclinical development of a third active substance. BioVersys focuses on the research and development of therapies to combat life-threatening, multidrug-resistant (MDR) bacterial infections (caused by antimicrobial resistance; AMR) and targeted modulation of the microbiome.

The company is developing a new, award-winning class of therapeutic agents called TRICs (transcriptional regulator inhibiting compounds). These drugs are able to simply eliminate bacterial resistance. Administering this proprietary invention from BioVersys together with existing antibiotics restores the efficacy of these antibiotics.

BioVersys’ CEO Dr. Marc Gitzinger comments: “We are grateful to the unwavering commitment of our knowledgeable long-term investors and welcome a number of new investors that understand the need for clinically meaningful solutions to address the burgeoning AMR crisis.”

Chairman of the Board Dr. Seng Chin Mah views the area of antibiotic resistance as “an attractive investment opportunity for strategic investors who are looking to impact global healthcare by preventing future pandemics, ensuring availability of pandemic-relevant drugs and participating in the upside potential of a changing regulatory and market environment.” He adds that BioVersys is “clearly one of the most compelling players” in this regard.

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.

Share

Official program